**Core tip:** The presented results indicate that male gender and a higher body mass index (BMI) are risk factors for advanced fibrosis in morbidly obese patients. There is also a positive correlation between cigarette smoking and liver stiffness in men. Our study highlights the fact that even in the upper BMI ranges, higher BMI bears greater risk for advanced disease. Therefore, in the morbidly obese population it may seem useful to emphasize the importance of weight reduction, even within the range of obesity.

INTRODUCTION
============

Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in the developed\[[@B1]\] and developing countries\[[@B2],[@B3]\] with estimated prevalence of 20%-40%, and is predicted to become the leading indication for liver transplantation in the United States\[[@B4]\]. NAFLD is tightly associated with the metabolic syndrome and its complications. Obesity is the most important risk factor for NAFLD, which affects as much as 74% of obese individuals\[[@B5]\]. Two large electronic databases have demonstrated a clear association between a higher body mass index (BMI), diabetes and male gender and the risk for NAFLD\[[@B6]\]. Furthermore, among morbidly obese patients, who are candidates for bariatric surgeries, the prevalence is even higher and reaches 96%\[[@B7]-[@B10]\].

NAFLD encompasses a wide spectrum of histological and clinical manifestations, ranging from simple steatosis to steatohepatitis, fibrosis and cirrhosis\[[@B11]\]. It is estimated that approximately 6%-13% of patients with simple steatosis progress to steatohepatitis, of which approximately 10%-29% reach liver cirrhosis within 10 years\[[@B12]\]. Moreover, non-alcoholic steatohepatitis cirrhosis is a known risk factor for hepatocellular carcinoma\[[@B4]\]. Given the relative high prevalence of severe fibrosis (12%) in morbidly obese patients\[[@B7]-[@B10]\], this population is especially prone to a detrimental course. Therefore, it is of upmost importance to identify those patients with high likelihood for advanced fibrosis who may later develop cirrhosis and hepatocellular carcinoma.

Several studies have aimed to find predictors and risk factors for advanced fibrosis, although most of them did not focus on morbidly obese population. In a study of 103 NAFLD patients who underwent serial liver biopsies to follow fibrosis progression rate\[[@B13]\], only type-2 diabetes mellitus (T2DM), BMI and initial stage of fibrosis were associated with a higher rate of disease progression. Of note, in this study only 68% of patients were obese. Sub-analysis of 3041 subjects from the Rotterdam study\[[@B14]\] revealed that liver stiffness above 8 kilopascals (kPa), as measured by FibroScan, was strongly associated with steatosis and T2DM. In this cohort the average BMI was 27, thus not representing a morbidly obese population. With respect to lifestyle and other co-morbidities, smoking and obstructive sleep-apnea were demonstrated to be positively associated with liver fibrosis\[[@B15],[@B16]\]. Once again, most of the patients were not morbidly obese with an average BMI of 34 and 28 respectively.

Given the scarce data regarding risk factors for advanced fibrosis in morbidly obese population, the aim of the present study was to investigate predictors for fibrosis, specifically in this high risk population, including detailed evaluation of lifestyle. To none invasively assess liver fibrosis we used transient elastography (FibroScan^®^), which is a validated tool to determine liver stiffness\[[@B17]\], and was demonstrated to be one of the most accurate tests for the non-invasive evaluation of liver fibrosis in NAFLD with a clinical prognostic value\[[@B18]\].

MATERIALS AND METHODS
=====================

We conducted a cross-sectional study among morbidly obese patients attending the bariatric clinic at the Tel-Aviv Medical Center between the years 2013-2014 with BMI above 40 or above 35 plus at least one co-morbidity (*i.e*., hypertension, type 2 diabetes, cardiovascular disease, lung disease and respiratory disorders), according to the Israeli Health Ministry indications published on 2013 (<http://www.health.gov.il/hozer/mr33_2013.pdf>). Patients with serum HBsAg or anti-hepatitis C virus antibodies, genetic liver diseases, autoimmune disease or high alcohol intake (≥ 30 g/d in men or ≥ 20 g/d in women)\[[@B19],[@B20]\] were excluded from the study. All procedures performed in this study were approved by the institutional research committee of the Tel-Aviv Medical Center and in accordance with the ethical standards of the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all participants included in the study.

Liver stiffness measurement
---------------------------

Liver stiffness measurement (LSM) was measured using the ''XL'' probe. LSM were considered representative only if they had at least 10 valid acquisitions with a success rate \> 60%\[[@B21]\]. All measurements were taken by the same operator (experience, \> 10000 measurements) which was blinded to other parameters of the patients. As previously described\[[@B22]\], the examination was performed with the patient lying down in the dorsal decubitus position with the right arm in maximal abduction. The tip of the probe transducer was placed on the skin, between the ribs at the level of the right lobe of the liver. The results were expressed in kPa and each LSM corresponds to the median of 10 validated measurements. The cut-off values for fibrosis stage were according to the suggested best cutoffs to distinguish between fibrosis levels among NAFLD patients\[[@B23],[@B24]\]: \< 7.1; F0-F1: 7.1-9.5 kPa; F2: 9.6-11.5; F3: \> 11.5; and F4: Significant fibrosis was defined as F ≥ 2, and advanced fibrosis was defined as F ≥ 3\[[@B25]-[@B27]\].

Demographic, health and lifestyle data
--------------------------------------

We collected data on age and gender, education, smoking status and amount, medical history including diabetes and medical treatment, nutrition, lifestyle habits and health status. All these data were collected using a structured and uniform questionnaire completed by all participants, tailored for the current study based on validated questionnaires used in national Israeli surveys\[[@B28]\]. Fasting blood test were available for a subsample of 40-48 patients.

Statistical analysis
--------------------

Statistical analyses were performed using SPSS version 22 (SPSS Inc., Chicago, IL, United States) software. Continuous variables are presented as means ± SD. To test differences in continuous variables between the two groups the independent samples *t*-test or the Mann-Whitney *U* test were performed. Associations between nominal variables were performed with the Pearson *χ*^2^ test. The Pearson correlation was used for the evaluation of the correlation between liver stiffness and other measurements. A multivariate logistic regression analysis was performed to test the adjusted association between significant liver stiffness and potential predictors. Using a receiver operating characteristic curve, the best BMI cutoff point to predict significant fibrosis was 40, which represents grade-3 obesity. To test the combined effect of male gender and BMI of 40 and above (high BMI), we created a new variable with three categories: Lower BMI plus female gender, either male gender or high BMI, both male gender and high BMI. One way ANOVA of variance was used to test the difference in the distribution of liver stiffness between the categories with a *P* for trend test. Pearson *χ*^2^ test was used to test the association between these categories and the categories of fibrosis severity with a *P* for trend test. *P* \< 0.05 was considered statistically significant for all analyses.

RESULTS
=======

Description of the study population
-----------------------------------

A total of 201 consecutive patients were recruited, of which 91 agreed to undergo Fibroscan exam, and 77 patients had a valid examination according to the accepted criteria\[[@B21]\]. As depicted in Table [1](#T1){ref-type="table"}, the average BMI was 41.71 ± 4.68 kg/m^2^, with a range between 32.25 to 56.36 kg/m^2^, 48 had a BMI of 40 and above. Alcohol consumption was very low and no patient had to be excluded due to excessive consumption. The available blood tests indicated impaired fasting glucose and mildly elevated triglycerides and ALT levels. Most patients (60%) had some level of fibrosis (F2 and above) according to the Fibroscan examination. Of note, 39% of the patients had advanced or severe fibrosis (F3 or F4), 21% had significant fibrosis (F2) and only 40% of the patients had minimal or no fibrosis (F0-F1) (Figure [1](#F1){ref-type="fig"}).

###### 

Clinical characteristics of the study population

  **Variable**                                             ***n*[1](#T1FN1){ref-type="table-fn"}**   **Mean ± SD**
  -------------------------------------------------------- ----------------------------------------- -----------------
  Age (yr)                                                 77                                        42.4 ± 12.98
  Gender (male) %                                          77                                        46.8
  BMI (kg/m[2](#T1FN2){ref-type="table-fn"})               77                                        41.71 ± 4.68
  Glucose (mg/dL) (\< 100)                                 48                                        116.81 ± 35.08
  Total cholesterol (mg/dL) (\< 200)                       42                                        191.97 ± 34.46
  LDL (mg/dL)                                              42                                        112.80 ± 33.05
  HDL (mg/dL)                                              40                                        44.19 ± 11.87
  TG (mg/dL) (\< 150)                                      42                                        182.38 ± 56.36
  ALT (U/L) (5-39)                                         47                                        44.28 ± 44.49
  AST (U/L) (7-40)                                         47                                        28.91 ± 20.11
  Success rate %                                           77                                        84.31 ± 13.55
  Stiffness                                                77                                        10.24 ± 6.27
  Sedentary time[2](#T1FN2){ref-type="table-fn"} (min/d)   77                                        263.84 ± 176.56
  Daily activity (score[3](#T1FN3){ref-type="table-fn"})   77                                        20.56 ± 3.47
  Alcohol servings/week                                    77                                        0.66 ± 1.67
  Current or past smokers %                                77                                        48.1

Indicates on the number of people with available measure;

Time spent by using a computer, watching television or reading;

Climbing stairs, short walking and house-keeping chores, *etc*. The higher the score the lower is the activity (1-every day, 5-never). BMI: Body mass index; LDL: Low density lipoprotein; HDL: High density lipoprotein; ALT: Alanine aminotransferase; AST: Aspartate transaminase; TG: Triglycerides.

![Distribution of liver stiffness levels according to Fibroscan.](WJH-9-91-g001){#F1}

Comparison between subjects with significant or advanced fibrosis and subjects with minimal or no fibrosis
----------------------------------------------------------------------------------------------------------

Male gender was significantly more prevalent in subjects with fibrosis level of F2 and above or F3 and above, as compared to subjects with minimal or no fibrosis (63% *vs* 22.6%, *P* \< 0.001 and 63.3% *vs* 36.2%, *P* = 0.020, respectively) (Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}). In addition, BMI was significantly higher in subjects with fibrosis level of F2 and above or F3 and above as compared to subjects with minimal or no fibrosis (42.99 ± 5.11 kg/m^2^ *vs* 39.82 ± 3.16 kg/m^2^, *P* \< 0.001 and 42.32 ± 5.3 kg/m^2^ *vs* 40.68 ± 3.96 kg/m^2^, *P* = 0.023, respectively) (Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}). No other significant differences were noted between groups in nutritional, physical activity and biochemical parameters (Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}). Of note, there was no correlation between ALT and fibrosis (correlation *r* = 0.17, *P* = 0.253).

###### 

Comparison between subjects with fibrosis degree F \< 2 and subjects with significant fibrosis degree F ≥ 2 (mean ± SD, unless otherwise stated)

  **Variable**                                             **F \< 2 (*n* = 31)**   **F ≥ 2 (*n* = 46)**   ***P***
  -------------------------------------------------------- ----------------------- ---------------------- ----------
  Gender (men) %                                           22.6                    63                     \< 0.001
  Age (yr)                                                 42.32 ± 13.89           42.96 ± 12.29          0.838
  Education (yr)                                           13.13 ± 2.05            13.78 ± 2.9            0.281
  BMI (kg/m[2](#T2FN2){ref-type="table-fn"})               39.82 ± 3.16            42.99 ± 5.11           \< 0.001
  Type 2 diabetes drugs (%)                                19.4                    17.4                   0.827
  All sugared soft drinks (cups/d)                         1.76 ± 2.74             1.38 ± 2.24            0.502
  Carbonated sugared drinks intake (cups/d)                0.99 ± 1.52             0.89 ± 1.98            0.816
  Diet carbonated drinks intake (cups/d)                   0.46 ± 0.98             0.88 ± 1.6             0.196
  Coffee intake (cups/d)                                   2.22 ± 1.87             1.77 ± 1.74            0.287
  Alcohol servings/week                                    0.97 ± 1.80             0.46 ± 1.56            0.189
  Current or past smokers (%)                              48.4                    47.8                   0.961
  Fruits intake (portions/d)                               1.71 ± 1.35             1.74 ± 1.31            0.924
  Vegetables intake (portions/d)                           2.77 ± 2.38             2.64 ± 1.93            0.788
  Fried food intake (portions/d)                           1.18 ± 1.25             1.08 ± 0.77            0.690
  Leisure time physical activity (min/wk)                  189 ± 83.06             237.69 ± 437.89        0.733
  Sedentary time[1](#T2FN1){ref-type="table-fn"} (min/d)   264.19 ± 171.7          263.61 ± 181.65        0.989
  Daily activity (score[2](#T2FN2){ref-type="table-fn"})   20.19 ± 2.83            20.8 ± 3.85            0.452
  Glucose (mg/dL)                                          113.72 ± 42.35          119.42 ± 28.13         0.580
  Total cholesterol (mg/dL)                                202.68 ± 37.79          182.24 ± 28.6          0.054
  LDL (mg/dL)                                              121.52 ± 38.77          104.04 ± 23.97         0.088
  HDL (mg/dL)                                              46.55 ± 11.42           41.83 ± 12.13          0.213
  Triglycerides (mg/dL)                                    170.73 ± 60.25          192 ± 52.3             0.228
  ALT (U/L)                                                34.89 ± 37.77           50.66 ± 48.13          0.237
  AST (U/L)                                                26.4 ± 24.47            30.78 ± 16.43          0.467
  GGT (U/L)                                                22.52 ± 12.01           43.06 ± 23.53          0.090

Time spent by using a computer, watching television or reading;

Climbing stairs, short walking and house-keeping chores, *etc*. The higher the score the lower is the activity (1-every day, 5-never). BMI: Body mass index; LDL: Low density lipoprotein; HDL: High density lipoprotein; ALT: Alanine aminotransferase; AST: Aspartate transaminase; GGT: Glutamyl transpeptidase.

###### 

Comparison between subjects with fibrosis degree F \< 3 and subjects with advanced fibrosis degree F ≥ 3 (mean ± SD, unless otherwise stated)

  **Variable**                                             **F \< 3 (*n* = 47)**   **F ≥ 3 (*n* = 30)**   ***P***
  -------------------------------------------------------- ----------------------- ---------------------- ---------
  Gender (male) %                                          36.2                    63.3                   0.020
  Age (yr)                                                 42.47 ± 14              43.07 ± 11.09          0.836
  Education (yr)                                           13.19 ± 2.59            14.03 ± 2.55           0.166
  BMI (kg/m[2](#T3FN2){ref-type="table-fn"})               40.68 ± 3.96            42.32 ± 5.3            0.023
  Type 2 diabetes drugs (%)                                17                      20                     0.741
  All sugared soft drinks (cups/d)                         1.64 ± 2.45             1.37 ± 2.46            0.635
  Carbonated sugared drinks intake (cups/d)                0.9 ± 1.55              0.98 ± 2.16            0.850
  Diet carbonated drinks intake (cups/d)                   0.73 ± 1.44             0.68 ± 1.33            0.890
  Coffee intake (cups/d)                                   1.96 ± 1.88             1.93 ± 1.69            0.951
  Alcohol (servings/wk)                                    0.87 ± 1.76             0.33 ± 1.47            0.152
  Current or past smokers (%)                              48.9                    46.7                   0.846
  Fruits intake (portions/d)                               1.57 ± 1.25             1.97 ± 1.4             0.204
  Vegetables intake (portions/d)                           2.43 ± 2.11             3.12 ± 2.07            0.162
  Fried food intake (portions/d)                           1.12 ± 1.12             1.12 ± 0.75            0.999
  Leisure time physical activity (min/wk)                  155.62 ± 89.96          355.71 ± 585.97        0.403
  Sedentary time[1](#T3FN1){ref-type="table-fn"} (min/d)   265.66 ± 178.79         261.00 ± 176.01        0.911
  Daily activity (score[2](#T3FN2){ref-type="table-fn"})   20.32 ± 3.49            20.93 ± 3.45           0.452
  Glucose (mg/dL)                                          117 ± 39.93             116.53 ± 27.08         0.964
  Total cholesterol (mg/dL)                                197.75 ± 37.39          180.41 ± 25            0.083
  LDL (mg/dL)                                              117.81 ± 35.94          101.61 ± 22.00         0.087
  HDL (mg/dL)                                              44.85 ± 11.16           42.82 ± 13.6           0.619
  Triglycerides (mg/dL)                                    176.28 ± 55.14          194.57 ± 58.84         0.328
  ALT (U/L)                                                36.5 ± 33.26            55.76 ± 56.26          0.147
  AST (U/L)                                                26.89 ± 21.99           31.89 ± 17.11          0.409
  GGT (U/L)                                                29.89 ± 26.25           43.4 ± 16.96           0.241

Time spent by using a computer, watching television or reading;

Climbing stairs, short walking and house-keeping chores, *etc*. The higher the score the lower is the activity (1-every day, 5-never). BMI: Body mass index; LDL: Low density lipoprotein; HDL: High density lipoprotein; ALT: Alanine aminotransferase; AST: Aspartate transaminase; GGT: Glutamyl transpeptidase.

Multivariate analysis for the prediction of significant or advanced fibrosis
----------------------------------------------------------------------------

In multivariate analysis, including age, gender and BMI, the positive association between male gender (OR = 7.93, 95%CI: 2.36-26.64, *P* = 0.001) and BMI (OR = 1.33, 95%CI: 1.11-1.60, *P* = 0.002) and fibrosis F ≥ 2 was maintained. Similarly, the positive association between male gender (OR = 2.92, 95%CI: 1.08-7.91, *P* = 0.035) and BMI (OR = 1.17, 95%CI: 1.03-1.33, *P* = 0.018) and fibrosis F ≥ 3 was maintained (Table [4](#T4){ref-type="table"}).

###### 

Multivariate analysis for the prediction of significant or advanced fibrosis

  **Variable**    **Model 1: F ≥ 2**   **Model 2: F ≥ 3**                      
  --------------- -------------------- -------------------- ------------------ -------
  Age (yr)        1.03 (0.99-1.08)     0.153                1.03 (0.98-1.07)   0.246
  Gender (male)   7.93 (2.36-26.64)    0.001                2.92 (1.08-7.91)   0.035
  BMI (kg/m^2^)   1.33 (1.11-1.60)     0.002                1.17 (1.03-1.33)   0.018

The models are adjusted for all variables listed in the model. BMI: Body mass index.

The dose response association of the combined categories of BMI of 40 and above (grade 3 obesity) and male gender with fibrosis level
-------------------------------------------------------------------------------------------------------------------------------------

Subjects were categorized to subgroups based on the combination of gender and BMI of 40 and above: Subgroup (1) women and BMI below 40; subgroup (2) either men or BMI of 40 and above; subgroup (3) both men and BMI of 40 and above. A significant dose response association was noted across these categories for stiffness as a continuous variable (*P* for trend = 0.001) (Figure [2A](#F2){ref-type="fig"}), for the rate of subjects with F ≥ 2 (*P* for trend \< 0.001) (Figure [2B](#F2){ref-type="fig"}) and for the rate of subjects with F ≥ 3 (*P* for trend = 0.011) (Figure [2C](#F2){ref-type="fig"}). The highest stiffness or prevalence of significant/advanced fibrosis was among men with a higher BMI.

![Dose response relationship of the combined categories of body mass index of 40 and above (grade 3 obesity) and male gender with fibrosis level. Women + BMI \< 40; *n* = 14, men or BMI ≥ 40; *n* = 42, men + BMI ≥ 40; *n* = 21). BMI: Body mass index.](WJH-9-91-g002){#F2}

Cigarette smoking and fibrosis level
------------------------------------

Twenty one of the men and 16 of the women were current or past smokers. Among them, there was a significant positive correlation between cigarette smoking measured by pack-years (number of packs multiplied with the number of years of smoking) and liver stiffness (*r* = 0.37, *P* = 0.025). However, stratification by gender reveled that this association existed among men (*r* = 0.54, *P* = 0.012) (Figure [3](#F3){ref-type="fig"}), but not among women (*r* = -0.10, *P* = 0.716).

![Correlation between pack-years and liver stiffness among ever smoking men (*n* = 21).](WJH-9-91-g003){#F3}

DISCUSSION
==========

The presented results indicate that male gender and a higher BMI are risk factors for advanced fibrosis in morbidly obese patients. Notably, there is also a positive correlation between cigarette smoking measured by pack-years and liver stiffness in men. Our data corroborate previous publications\[[@B5],[@B7]-[@B10]\], demonstrating high rate of NAFLD with significant percent of severe (F4) fibrosis in morbidly obese patients, which in our population reached approximately 25% of the patients. Given the magnitude of the disease in the morbidly obese patients, only few attempts have been performed to stratify the risk for advanced fibrosis in this unique population, mostly among patients undergoing bariatric surgery. Ong et al\[[@B29]\] have found in 212 consecutive morbidly obese patients in whom liver biopsy was taken during bariatric surgery, that waist to hip ratio and AST levels were independently associated with severe fibrosis. In our cohort, liver enzymes were not predictive of advanced fibrosis. In another study\[[@B7]\] which obtained liver biopsy from 181 patients undergoing bariatric surgery, only age was significantly associated with advanced disease (moderate and severe fibrosis), in contrast to our results which did not show such an association (Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}). In line with our results, Dixon et al\[[@B8]\] have found in 105 consecutive biopsied bariatric patients that advanced fibrosis was associated with male gender and not with the presence of T2DM. In contrast, Beymer et al\[[@B9]\] has found T2DM as the only predictor to advanced fibrosis. This discrepancy may be explained by systemic insulin resistance characterizing most of the patients in the aforementioned cohorts who have not developed overt diabetes yet. This assumption is supported by the higher C-peptide level found in patients with advance fibrosis in Dixon's cohort\[[@B8]\]. Interestingly, a recent cohort analyzing 134 South Indian patients have found arterial hypertension as a sole independent risk factor for fibrosis\[[@B30]\].

In our study we have extended the search for advanced liver fibrosis predictors toward diet elements, eating behavior and lifestyle variables, all of which have shown an association with obesity in general\[[@B31]\] and some of them with NAFLD in particular\[[@B32]\]. Whereas the association between active and passive smoking and NAFLD has been already demonstrated\[[@B33]\], we succeeded to show a significant positive correlation between cigarette smoking measured by pack-years and liver stiffness in men (Figure [2](#F2){ref-type="fig"}). Our findings are corroborated by the data of the Multicenter Nonalcoholic Steatohepatitis Clinical Research Network generated from 1081 patients\[[@B16]\], in which multivariate analysis has demonstrated 1.6 fold increased odds for advanced fibrosis among those with a smoking history of ≥ 10 pack-years. Among non-diabetics, a history of ≥ 10 pack-years was associated with even a higher chance of 2.5 fold for advanced fibrosis. Multiple mechanisms may be involved in smoking injury, such as insulin resistance, oxidative stress and hypoxia\[[@B16]\]. Further studies are needed to confirm this finding among morbid obese patients and to elucidate this phenomenon.

We failed to find an association between liver stiffness and dietary parameters or eating patterns in this study. This lack of association may stem from potential sources of bias that need to be considered. First, recall and reporting bias may exist, especially on lifestyle habits and partially because of social desirability among obese population\[[@B34]\]. The bias was minimized by the use of structured and validated questionnaires. Also, no information about the purpose and the hypotheses of the study was provided to the participants in order to minimize the report bias. In addition, the interview was performed before receiving the results of the Fibroscan and thus the information bias is expected to be non-differential. Second, a measurement of liver stiffness is not the gold standard for the assessment of liver fibrosis. However, the Fibroscan test with the XL transducer is adjusted for patients with obesity and morbid obesity and compared with the standard transducer leads to lower rates of test failure (1.1% *vs* 16%) and an established validity\[[@B17],[@B21]\]. However, among obese subjects, unreliable results may still be observed with the XL probe\[[@B35]\]. Nevertheless, despite this disadvantage, Fibroscan was demonstrated to be one of the most accurate tests for the non-invasive diagnosis of liver fibrosis in NAFLD\[[@B18]\].

In conclusion, our study highlights the fact in even in the upper BMI ranges, higher BMI bears greater risk for advanced disease. In addition, male gender may a risk factor for advanced disease in the morbidly obese population. The suggested association with the degree of smoking in men will have to be confirmed in further studies with a larger sample size.
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